Tonix Pharmaceuticals Holding Income Statement (2011-2026) | TNXP

Income Statement Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Sep2016 Dec2016 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Shares Outstanding (Entity) (Quarter)
541.00631.00563.00864.000.00M0.00M0.00M0.00M0.00M0.01M0.01M
Revenue & cost
Revenue (Quarter)
4.74M3.63M3.54M3.99M3.78M2.48M2.21M2.82M2.58M2.43M2.00M3.29M5.39M6.88M
Gross Profit (Quarter)
1.61M1.41M0.82M-1.16M1.27M1.40M1.49M-1.27M1.92M4.33M5.30M
Operating items
Research & Development (Quarter)
18.13M13.08M22.30M18.42M16.58M22.20M24.67M26.51M21.98M21.05M17.12M12.86M9.70M9.11M8.30M7.44M10.82M9.29M16.94M18.21M
Selling, General & Administrative (Quarter)
5.43M5.45M7.18M8.01M6.76M7.39M8.05M7.39M7.03M8.71M11.62M9.31M7.50M7.71M15.58M10.10M16.20M25.70M35.68M28.62M
Other Operating Expenses (Quarter)
2.37M2.37M1.66M62.32M1.55M1.18M0.94M3.27M1.37M1.06M1.58M
Operating Expenses (Quarter)
23.56M18.54M29.48M26.44M23.34M29.59M32.73M33.90M29.00M32.14M31.11M23.83M79.52M18.38M25.06M18.48M30.29M36.36M53.68M48.41M
Operating Income (Quarter)
-23.56M-18.54M-29.48M-26.44M-23.34M-29.59M-32.73M-33.90M-29.00M-28.15M-27.33M-21.35M-77.32M-15.55M-22.48M-16.05M-28.30M-33.07M-48.29M-41.54M
EBIT (Quarter)
-23.56M-18.54M-29.48M-26.44M-23.34M-29.59M-32.73M-33.90M-29.00M-28.15M-27.33M-21.35M-77.32M-15.55M-22.48M-16.05M-28.30M-33.07M-48.29M-41.54M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.01M-0.07M0.02M0.20M0.61M1.05M0.90M0.17M0.65M0.02M0.00M0.39M1.23M1.34M1.35M
Other Non Operating Income (Quarter)
0.90M0.65M0.17M0.01M7.00M-0.61M0.59M-2.09M-1.16M
Non Operating Income (Quarter)
0.00M0.94M
Net income details
EBT (Quarter)
-23.58M-18.67M-29.71M-26.57M-24.15M-29.14M-31.83M-33.14M-29.14M-29.23M-26.80M-23.14M-78.89M-16.90M-22.55M-15.78M-28.34M-31.87M-46.82M-40.34M
Profit After Tax (Quarter)
-23.55M-18.53M-29.53M-26.42M-23.14M-33.70M-15.14M-33.01M-28.36M-27.98M-27.32M-14.94M-78.78M-16.90M-22.55M-16.83M-28.27M-31.87M-46.82M-40.34M
Income from Continuing Operations (Quarter)
-23.58M-18.67M-29.71M-26.57M-24.15M-29.14M-31.83M-33.14M-29.14M-29.23M-26.80M-23.14M-78.89M-16.90M-22.55M-15.78M-28.34M-31.87M-46.82M-40.34M
Consolidated Net Income (Quarter)
-23.58M-18.67M-29.71M-26.57M-24.15M-29.14M-31.83M-33.14M-29.14M-29.23M-26.80M-23.14M-78.89M-16.90M-22.55M-15.78M-28.34M-31.87M-46.82M-40.34M
Income towards Parent Company (Quarter)
-23.58M-18.67M-29.71M-26.57M-24.15M-29.14M-31.83M-33.14M-29.14M-29.23M-26.80M-23.14M-78.89M-16.90M-22.55M-15.78M-28.34M-31.87M-46.82M-40.34M
Preferred Dividend Payments (Quarter)
4.25M2.40M
Net Income towards Common Stockholders (Quarter)
-23.55M-18.53M-29.55M-26.57M-27.39M-28.98M-34.08M-33.01M-28.36M-27.98M-27.32M-14.94M-78.78M-14.21M-22.11M-16.83M-28.27M-32.01M-46.91M-40.19M
Additional items
EPS (Basic) (Quarter)
-0.05M-0.03M-0.05M-0.03M-0.02M-0.01M-0.02M-0.01M-0.01M-0.01M-0.01M-591.06-0.00M-22.88-30.02-2.84-3.86-3.59-5.51-2.93
EPS (Diluted) (Quarter)
-0.04M-0.03M-0.05M-0.03M-0.02M-0.01M-0.02M-0.01M-0.01M-0.01M-0.01M-591.06-0.00M-22.88-30.02-2.84-3.86-3.59-5.51-2.93
Shares Outstanding (Quarter)
518.00573.00563.00816.000.00M0.00M0.00M0.00M0.00M0.00M0.01M0.03M0.04M0.62M0.74M5.93M7.33M8.92M8.51M13.71M
Shares Outstanding (Diluted) (Quarter)
524.00579.00569.00816.000.00M0.00M0.00M0.00M0.00M0.00M0.01M0.03M0.04M0.62M0.74M5.93M7.33M8.92M8.51M13.71M
EBITDA (Quarter)
-23.56M-18.54M-29.48M-26.44M-23.34M-29.59M-32.73M-33.90M-29.00M-28.15M-27.33M-21.35M-77.32M-15.55M-22.48M-16.05M-28.30M-33.07M-48.29M-41.54M
Interest Expenses (Quarter)
0.02M0.14M0.15M0.16M1.01M0.16M0.15M0.14M0.14M1.25M0.12M1.79M1.57M1.36M0.07M0.12M0.04M0.04M-0.12M0.14M